Genprex, Inc. GNPX
Set alert
At close · Oct 30
After hours · Oct 30, 7:55 PM ET
- YTD
- -94.18%
- 1 year
- -98.38%
- Open
- 2.02
- Prev close
- 2.04
- Mkt cap
- 1.84M
- Vol
- 184.02K
- Avg vol
- 281.76K
- EPS
- -9.35
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.02
- High
- 2.27
- Forward P/E
- -0.43
- Beta
- -1.29
- Short ratio
- 0.02
- Inst. own
- 10.91%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2024
- 50-d avg
- 1.36
- 200-d avg
- 1.75
- 1y target
- 7.50
News
4 days ago prnewswire.com
Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting
Research explores the role of TUSC2, the therapeutic gene used in Reqorsa® Gene Therapy in mitochondrial biology and cellular aging, supporting investigation of potential applications beyond oncology…
-
1 week ago benzinga.com
Genprex Highlights New Peer-Reviewed Research In Mice Identifying Important Role For TUSC2 Tumor Suppressor Gene In Maintaining Cellular Processes Associated With Healthy Brain Aging
Collaborators publish new peer-reviewed study identifying sex-specific effects of TUSC2 loss on mitochondrial function, protein homeostasis, and synaptic pathways, alongside molecular similarities…
1 week ago prnewswire.com
Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging
Collaborators publish new peer-reviewed study identifying sex-specific effects of TUSC2 loss on mitochondrial function, protein homeostasis, and synaptic pathways, alongside molecular similarities…
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience…
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. Chemomab Therapeutics…
1 month ago prnewswire.com
Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Company Presentation to Highlight Lead Clinical Oncology Program and Preclinical Diabetes Program AUSTIN, Texas, Sept. 8, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:…
2 months ago prnewswire.com
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy
Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials AUSTIN, Texas, Aug. 18, 2026 /PRNewswire/ -- Genprex, Inc.…
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding…
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. Supernus…
-
3 months ago benzinga.com
Genprex Partners With Roche Diagnostics To Validate Biomarkers For Patient Selection In Clinical Trials For Non-Small Cell Lung Cancer
Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker. Genprex's initial research demonstrated that high TROP2…
3 months ago prnewswire.com
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria AUSTIN, Texas, Aug. 3, 2026…
-
4 months ago benzinga.com
Genprex Receives Notice Of Allowance From CIPO For Patent Covering Use Of Reqorsa Gene Therapy In Combination With Either PD-1 Or PD-L1 Antibodies For Treatment Of Lung Cancer
Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq®AUSTIN, Texas, June 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company")
4 months ago prnewswire.com
Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer
Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq® AUSTIN, Texas, June 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company")…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
4 months ago prnewswire.com
Genprex to Participate at BIO International Convention 2026
The BIO International Convention Brings Together More Than 20,000 Biotech Industry Leaders From Around The World AUSTIN, Texas, June 17, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
5 months ago prnewswire.com
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting
Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients Identified Biomarkers May Predict Patient Response,…
5 months ago prnewswire.com
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Texas, May 14, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a…
5 months ago benzinga.com
Top 3 Health Care Stocks That Are Set To Fly In Q2
The health care sector has oversold stocks with RSI below 30, presenting an opportunity for traders to buy undervalued companies.
6 months ago prnewswire.com
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
Strengthens Patent Estate and Expands Protection in Another Target Market AUSTIN, Texas, April 30, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage…
6 months ago prnewswire.com
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Texas, April 28, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a…
6 months ago prnewswire.com
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
AUSTIN, Texas, April 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for…
6 months ago prnewswire.com
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
Research on Biomarkers May Help Enrich Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials, Potentially Predicting Patient Response to REQORSA Treatment Demonstrates Commitment to Tailored Treatment…
6 months ago prnewswire.com
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene Therapy REQORSA Induced Apoptosis and Decreased Tumor Volume in ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Cell…
7 months ago defenseworld.net
Cullinan Therapeutics (NASDAQ:CGEM) versus Genprex (NASDAQ:GNPX) Head to Head Comparison
Genprex (NASDAQ: GNPX - Get Free Report) and Cullinan Therapeutics (NASDAQ: CGEM - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the…
7 months ago benzinga.com
Top Ranking Stock Picker From Congress Is Back Buying Small Cap Stocks Again: Here Are The Tickers
A Congress member continues to buy small cap stocks. Here's the latest names added to his investment portfolio in March 2026.
7 months ago defenseworld.net
Genprex (GNPX) Expected to Announce Quarterly Earnings on Friday
Genprex (NASDAQ: GNPX - Get Free Report) will likely be issuing its resultson Friday, March 27th. Analysts expect the company to announce earnings of ($13.00) per share for the quarter. Genprex Price…
7 months ago prnewswire.com
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
Research Collaborators Identify Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy REQORSA is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer…
7 months ago prnewswire.com
Genprex to Participate at BIO Europe Spring 2026
AUSTIN, Texas, March 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for…
8 months ago benzinga.com
Congressman Who Bought Small-Cap Stocks In 2025 Is Back With New 2026 Pick: Here's What He's Buying
A member of Congress is buying stock in two small cap companies in 2026. Here's the stocks and why investors should be watching.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
8 months ago prnewswire.com
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
Japanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'sTecentriq® AUSTIN, Texas, Feb. 23, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company")…
8 months ago prnewswire.com
Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq® Company Adds Additional Acclaim-3 Clinical Trial Site AUSTIN, Texas, Feb. 10, 2026 /PRNewswire/…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
10 months ago benzinga.com
Move Over, Pelosi: This Congress Member Posted 2025's Best Market Return With A 52% Gain
The list of the top 10 members of Congress for 2025 investment portfolio gains. Where did Marjorie Taylor Greene rank and how close was Nancy Pelosi to the Top 10?
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
11 months ago benzinga.com
Congressman Buys Shares Of Small Cap Lift Truck Company You've Probably Never Heard Of
A congressman bought shares of a small cap company recently. Here's a look at the stock and why it's drawing attention.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
1 year ago benzinga.com
Netflix Posts Downbeat Earnings, Joins Aveanna Healthcare, Texas Instruments And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Netflix Posts Downbeat Earnings, Joins Aveanna Healthcare, Texas Instruments And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
1 year ago benzinga.com
Why J.B. Hunt Transport Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Why J.B. Hunt Transport Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
1 year ago benzinga.com
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session